Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we define the basal and ATRA dependent RARα interactome in a RARα-overexpressing breast cancer cellular model, identifying 28 nuclear proteins.
|
30532072 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall this study supports the proof of principle that the epigenetic functional plasticity of the mammary epithelial cell RARA mechanism, which is essential for normal morphogenetic processes, is necessary to deter breast cancer onset/progression consequent to the insidious action of physiological RA.
|
27894085 |
2016 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Genomic landscapes of breast fibroepithelial tumors.
|
26437033 |
2015 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Array comparative genomic hybridization and gene expression arrays were used to characterize RARA amplifications and expression in 103 breast cancer samples.
|
23830798 |
2013 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data indicate that retinoic acid receptor alpha may be a novel therapeutic target and a predictive factor for oestrogen receptor alpha-positive breast cancer patients treated with adjuvant tamoxifen.
|
23868472 |
2013 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This provides proof-of-principle that coamplification of ERBB2 and RARA can be exploited for the stratified and targeted therapy of a novel subtype of breast cancer patients, with an approach characterized by tumor cell selectivity and low predicted toxicity.
|
22056878 |
2012 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The functional consequence of the interplay between c-Myc oncogene expression and the RARγ to RARα/β balance suggests that prevalence of RARγ over-RARα/β expression levels in breast cancer accompanied by c-Myc amplification or over-expression in breast cancer should be predictive of response to treatment with RARα-isotype-specific agonists and warrant monitoring during clinical trials.
|
22920668 |
2012 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The methylation rate of RAR-β2 in breast cancer and precancerous lesions of breast cancer were higher than that of normal tissues.
|
20865461 |
2011 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additional FISH studies that use probes to the SMS, RARA, and TP53 genes are an effective way to determine the true HER2 amplification status in patients with polysomy 17 and they have important potential implications for guiding HER2-targeted therapy in breast cancer.
|
21947821 |
2011 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The basal expression of RARα1, the only RARα isoform that was expressed in breast cancer cell lines and in most breast tumors, was supported by apo-ER but was unaffected by OH-Tam; RAR-β and -γ were not regulated by apo-ER.
|
21299862 |
2011 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Retinoic acid receptor alpha (RARA) and other target sequences at 17p11.2 often represent the amplicons expressed in breast cancer, not in AML.
|
20804918 |
2010 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The anticancer effect of RARalpha, together with the newly discovered pro-proliferative role of RARgamma, suggests that specific activation of RARalpha and inhibition of RARgamma might be effective in breast cancer therapy.
|
20453882 |
2010 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
STARD3 and RARA also hold clinical relevance, the former having been shown to function in steroidogenesis and therefore implicated in hormone-receptor-positive breast cancer.
|
20100636 |
2010 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, we found no evidence that these common polymorphisms of the MTHFR and MTR genes are associated with promoter methylation of E-cadherin, p16, and RAR-beta2 genes in breast cancer.
|
19240236 |
2009 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Five lines of evidence suggest that melatonin works via epigenetic processes: (1) melatonin influences transcriptional activity of nuclear receptors (ERalpha, GR and RAR) involved in the regulation of breast cancer cell growth; (2) melatonin down-regulates the expression of genes responsible for the local synthesis or activation of estrogens including aromatase, an effect which may be mediated by methylation of the CYP19 gene or deacetylation of CYP19 histones; (3) melatonin inhibits telomerase activity and expression induced by either natural estrogens or xenoestrogens; (4) melatonin modulates the cell cycle through the inhibition of cyclin D1 expression; (5) melatonin influences circadian rhythm disturbances dependent on alterations of the light/dark cycle (i.e., light at night) with the subsequent deregulation of PER2 which acts as a tumor suppressor gene.
|
18592373 |
2009 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Another shared breakpoint was identified within the approximately 17-kb RARA intron 2 involving 2 t-APL cases arising after mitoxantrone treatment for MS and breast cancer, respectively.
|
18650449 |
2008 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Melatonin, via its MT1 receptor, but not the MT2 receptor, can modulate the transcriptional activity of various nuclear receptors - estrogen receptor alpha (ERalpha) and retinoic acid receptor alpha (RARalpha), but not ERbeta- in MCF-7, T47D, and ZR-75-1 human breast cancer cell lines.
|
18705646 |
2008 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Forced expression of RAR-beta2 reverts the malignant phenotype of RAR-beta2-negative breast cancer cells and reconstitutes retinoid sensitivity in these cells.
|
17608728 |
2007 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, in breast cancer MCF-7 cells it down-regulated RARalpha protein expression with no effect on its RARalpha mRNA.
|
15171703 |
2004 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In most breast carcinomas and in breast cancer cell lines, retinoic acid receptor beta (RARbeta) is lost or down-regulated, whereas retinoic acid receptor alpha and gamma (RARalpha, gamma) and retinoid X receptors (RXRalpha, beta, gamma) are variably expressed.
|
15375546 |
2004 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several groups demonstrated that this is also true for the RAR-beta2 in breast cancer by treating breast cancer cell lines with a demethylating agent and examining expression of the RAR-beta2 gene in response to a challenge with retinoic acid.
|
11501579 |
2001 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Using methylation-specific polymerase chain reaction and LOH analysis, we found that biallelic inactivation via epigenetic changes of both maternal and paternal alleles, or epigenetic modification of one allele combined with genetic loss of the remaining allele, could completely suppress RAR beta2 expression in breast cancer.
|
11141504 |
2001 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
RAR-beta2 expression was studied by reverse transcription-polymerase chain reaction (RT-PCR) analysis in eight breast cancer cell lines that were either treated with the demethylating agent 5-aza-2'-deoxycytidine and subsequently with all-trans-retinoic acid (ATRA) or left untreated.
|
10814678 |
2000 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Regulation of the human retinoic acid receptor alpha gene in the estrogen receptor negative human breast carcinoma cell lines SKBR-3 and MDA-MB-435.
|
8912864 |
1996 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Estradiol regulation of the human retinoic acid receptor alpha gene in human breast carcinoma cells is mediated via an imperfect half-palindromic estrogen response element and Sp1 motifs.
|
7585542 |
1995 |